AB Corporate Bond ETF (NASDAQ:EYEG) Shares Cross Below Two Hundred Day Moving Average – Here’s Why

AB Corporate Bond ETF (NASDAQ:EYEG) shares crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $35.43 and traded as low as $34.75. AB Corporate Bond ETF shares last traded at $34.77, with a volume of 60 shares trading hands.

AB Corporate Bond ETF Price Performance

The stock’s fifty day moving average is $35.11 and its 200-day moving average is $35.43. The stock has a market capitalization of $27.82 million, a PE ratio of -20.70 and a beta of 0.17. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.07 and a quick ratio of 3.07.

AB Corporate Bond ETF Cuts Dividend

The company also recently disclosed a monthly dividend, which was paid on Tuesday, July 7th. Shareholders of record on Wednesday, July 1st were given a $0.1358 dividend. The ex-dividend date was Wednesday, July 1st. This represents a c) dividend on an annualized basis and a dividend yield of 4.7%. AB Corporate Bond ETF’s dividend payout ratio is -102.98%.

Institutional Investors Weigh In On AB Corporate Bond ETF

Institutional investors have recently modified their holdings of the business. Kestra Advisory Services LLC acquired a new position in AB Corporate Bond ETF in the 4th quarter worth about $34,000. Jane Street Group LLC purchased a new position in AB Corporate Bond ETF during the second quarter worth approximately $232,000. Finally, Wealth Enhancement Advisory Services LLC boosted its position in AB Corporate Bond ETF by 32.5% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 157,702 shares of the specialty pharmaceutical company’s stock worth $5,634,000 after purchasing an additional 38,685 shares in the last quarter. 64.16% of the stock is currently owned by institutional investors and hedge funds.

About AB Corporate Bond ETF

EyeGate Pharmaceuticals, Inc is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.